Steven W Elmore
Overview
Explore the profile of Steven W Elmore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
6077
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tao Z, Wang X, Chen J, Ingram J, Jin S, Judge R, et al.
ACS Med Chem Lett
. 2021 Jun;
12(6):1011-1016.
PMID: 34141086
BCL-X, an antiapoptotic member of the BCL-2 family of proteins, drives tumor survival and maintenance and thus represents a key target for cancer treatment. Herein we report the rational design...
2.
Salem A, Tao Z, Bueno O, Chen J, Chen S, Edalji R, et al.
Mol Cancer Ther
. 2021 Mar;
20(6):999-1008.
PMID: 33785651
Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other blood-related cancers. Reflecting the large and hydrophobic...
3.
Wang L, Doherty G, Judd A, Tao Z, Hansen T, Frey R, et al.
ACS Med Chem Lett
. 2020 Oct;
11(10):1829-1836.
PMID: 33062160
Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-X inhibitor that selectively and potently induces apoptosis in BCL-X-dependent tumor cells. This molecule was generated by re-engineering our...
4.
McDaniel K, Wang L, Soltwedel T, Fidanze S, Hasvold L, Liu D, et al.
J Med Chem
. 2017 Sep;
60(20):8369-8384.
PMID: 28949521
The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest. An effort to generate novel...
5.
Bui M, Lin X, Albert D, Li L, Lam L, Faivre E, et al.
Cancer Res
. 2017 Apr;
77(11):2976-2989.
PMID: 28416490
ABBV-075 is a potent and selective BET family bromodomain inhibitor that recently entered phase I clinical trials. Comprehensive preclinical characterization of ABBV-075 demonstrated broad activity across cell lines and tumor...
6.
Wang L, Pratt J, Soltwedel T, Sheppard G, Fidanze S, Liu D, et al.
J Med Chem
. 2017 Apr;
60(9):3828-3850.
PMID: 28368119
Members of the BET family of bromodomain containing proteins have been identified as potential targets for blocking proliferation in a variety of cancer cell lines. A two-dimensional NMR fragment screen...
7.
Hasvold L, Sheppard G, Wang L, Fidanze S, Liu D, Pratt J, et al.
Bioorg Med Chem Lett
. 2017 Mar;
27(10):2225-2233.
PMID: 28268136
An NMR fragment screen for binders to the bromodomains of BRD4 identified 2-methyl-3-ketopyrroles 1 and 2. Elaboration of these fragments guided by structure-based design provided lead molecules with significant activity...
8.
Xiao Y, Nimmer P, Sheppard G, Bruncko M, Hessler P, Lu X, et al.
Mol Cancer Ther
. 2015 May;
14(8):1837-47.
PMID: 26013319
Hyperexpression of antiapoptotic BCL-2 family proteins allows cells to survive despite the receipt of signals that would ordinarily induce their deletion, a facet frequently exploited by tumors. Tumors addicted to...
9.
Bruncko M, Wang L, Sheppard G, Phillips D, Tahir S, Xue J, et al.
J Med Chem
. 2015 May;
58(9):4089.
PMID: 25933255
No abstract available.
10.
Leverson J, Phillips D, Mitten M, Boghaert E, Diaz D, Tahir S, et al.
Sci Transl Med
. 2015 Mar;
7(279):279ra40.
PMID: 25787766
The BCL-2/BCL-XL/BCL-W inhibitor ABT-263 (navitoclax) has shown promising clinical activity in lymphoid malignancies such as chronic lymphocytic leukemia. However, its efficacy in these settings is limited by thrombocytopenia caused by...